-
Setback for Orexigen - Analyst Blog
Wednesday, February 2, 2011 - 10:30am | 696Orexigen Therapeutics Inc. (OREX) was dealt a severe blow by the US Food and Drug Administration (FDA) when the regulatory body declined to approve its obesity drug, Contrave in the present form and issued a complete response letter (CRL). Contrave, which aimed at addressing the physiological and...
-
Goldman On Thermo Fisher's Strong 4Q
Wednesday, February 2, 2011 - 9:53am | 162Goldman Sachs has published a research report on Thermo Fisher Scientific, Inc. (NYSE: TMO) after the company reported a better than expected 4Q. In the report, Goldman writes "TMO reported better than expected 4Q2010 EPS of $1.00 vs. our $0.96 estimate and Street $0.95 driven by stronger gross...
-
Capstone Upgrades AMAG To Buy
Wednesday, February 2, 2011 - 8:18am | 48Analysts at Capstone upgrade AMAG Pharmaceuticals Inc (NASDAQ: AMAG) from “hold” to “buy.” The target price for AMAG is set to $21. AMAG shares fell 0.28% to close at $17.75 yesterday. More Analyst Ratings here
-
Thermo Fisher Scientific Reports Mixed Results (TMO)
Wednesday, February 2, 2011 - 7:31am | 153Thermo Fisher Scientific Inc. (NYSE: TMO) on Wednesday morning released financial results that beat Wall Street earnings expectations, while missing revenue estimates. Thermo Fisher Scientific Inc reported that its 4th quarter net income rose to $297.5 million, or 75 cents per share, up from $273.3...
-
Thermo Fisher Reports Q4 EPS of $1.00
Wednesday, February 2, 2011 - 7:12am | 58Thermo Fisher Scientific Inc (NYSE: TMO) reports its Q4 adjusted EPS at $1.00, beating the consensus of $0.95. TMO reports its Q4 revenue at $2.78 billion, versus the consensus of $2.8 billion. TMO shares gained 0.24% to close at $57.41 yesterday. Read more from Benzinga's Company news.
-
Earnings Scheduled For February 2 (YUM, MAT, V, AGN, MRO, HSY, NWS, NDAQ, GNW, AOL, TWX, TMO, AMP, WHR, BMC, ACE, HIG)
Wednesday, February 2, 2011 - 4:51am | 437Yum! Brands Inc (NYSE: YUM) is expected to report its Q4 EPS at $0.60 on revenue of $3.50 billion. Mattel Inc (NASDAQ: MAT) is projected to post its earnings at $0.86 per share on revenue of $2.09 billion in fourth-quarter. Visa (NYSE: V) is expected to report its Q1 earnings at $1.20 per share on...
-
Qiagen Outpaces EPS Est, Revenues Lag - Analyst Blog
Tuesday, February 1, 2011 - 1:31pm | 541Qiagen (QGEN) reported an EPS of 15 cents for the fourth quarter of fiscal 2010 compared to 18 cents in the year-ago period. However, after making some adjustments the EPS came in at 26 cents, beating the Zacks Consensus Estimate by a penny. Adjusted EPS for the prior-year quarter was 24 cents....
-
Qiagen Outpaces EPS Est, Revenues Lag - Analyst Blog
Tuesday, February 1, 2011 - 1:15pm | 541Qiagen (QGEN) reported an EPS of 15 cents for the fourth quarter of fiscal 2010 compared to 18 cents in the year-ago period. However, after making some adjustments the EPS came in at 26 cents, beating the Zacks Consensus Estimate by a penny. Adjusted EPS for the prior-year quarter was 24 cents....
-
Jefferies Reiterates Buy Rating on PAREXEL International (PRXL)
Tuesday, February 1, 2011 - 10:22am | 103Jefferies is out with a research report this morning, where it reiterates its Buy rating on PAREXEL International (NASDAQ: PRXL); it has a $28.00 price target on the stock. The Jefferies analysts cited the company's recent earnings announcement, which showed that F2Q11 results were in line on...
-
QIAGEN Reports Q4 EPS of $.26 vs. $.25
Monday, January 31, 2011 - 5:19pm | 205QIAGEN N.V. (Nasdaq: QGEN) today announced results of operations for the fourth quarter and the 12-month period ended December 31, 2010. Net sales and adjusted earnings per share for both periods were in line with expectations provided by QIAGEN on November 8, 2010. Net sales in the fourth quarter...
-
Earnings Preview: Alkermes - Analyst Blog
Monday, January 31, 2011 - 2:03pm | 879Alkermes Inc.(ALKS) is all set to announce its third quarter fiscal 2011 results on February 3, 2011 after the close of market. The Zacks Consensus Estimate for the third quarter of fiscal 2011 hints at a loss of $0.15 per share, as against a loss of $0.03 incurred in the year ago quarter....
-
Earnings Preview: Alkermes - Analyst Blog
Monday, January 31, 2011 - 1:30pm | 879Alkermes Inc.(ALKS) is all set to announce its third quarter fiscal 2011 results on February 3, 2011 after the close of market. The Zacks Consensus Estimate for the third quarter of fiscal 2011 hints at a loss of $0.15 per share, as against a loss of $0.03 incurred in the year ago quarter....
-
Piper Jaffray Raises PT On Covance To $64
Friday, January 28, 2011 - 8:44am | 27Piper Jaffray has raised the price target on Covance, Inc. (NYSE: CVD) from $43 to $64 and maintains its Neutral rating.
-
Jefferies Raises PT On Covance To $52
Friday, January 28, 2011 - 8:30am | 27Jefferies & Company has raised the price target on Covance, Inc. (NYSE: CVD) from $45 to $52 and maintains its Hold rating.
-
Cost Control Helps Amylin Cut Loss - Analyst Blog
Thursday, January 27, 2011 - 11:31am | 1270Amylin Pharmaceuticals (AMLN) reported a net loss of 8 cents per share in the fourth quarter of 2010, well below the Zacks Consensus Estimate and the year-ago loss of 32 cents. Full year 2010 loss came in at 94 cents, significantly below the Zacks Consensus Estimate of a loss of $1.26 and the...